Literature DB >> 10716484

Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion.

B Zhu1, Y Sun, R E Sievers, A E Browne, S Pulukurthy, K Sudhir, R J Lee, T M Chou, K Chatterjee, W W Parmley.   

Abstract

OBJECTIVES: We sought to assess the comparative effects of pretreatment with captopril and losartan on myocardial infarct size and arrhythmias in a rat model of ischemia-reperfusion.
BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) inhibit the renin-angiotensin system in different ways. However, the comparative effects of pretreatment with ACE inhibitors or ARBs on acute myocardial infarct size and arrhythmias are unknown.
METHODS: We randomly assigned 117 female Sprague-Dawley rats into three groups: group N was the normal control; group C was given 40 mg/kg body weight per day of captopril in drinking water; and group L was given 40 mg/kg per day of losartan in drinking water. After 10 weeks of pretreatment, 25 rats in each group were subjected to 17 min of left anterior descending coronary artery occlusion and 2 h of reperfusion with hemodynamic and electrocardiographic monitoring. Fourteen rats in each group had blood samples drawn and aortic rings removed to study vascular reactivity.
RESULTS: Mortality during ischemia and reperfusion was lower in combined groups L and C than in group N (4.2% vs. 19.2%, p = 0.042). Rats treated with losartan had significantly higher levels of angiotensin II in their plasma. Hemodynamic variables were not significantly different among the three groups. The thresholds of ventricular fibrillation (VF) before occlusion and after reperfusion were significantly higher in groups L and C than in group N (1.99 +/- 0.24 and 1.93 +/- 0.27 vs. 1.23 + 0.17 mA, p = 0.04; 2.13 +/- 0.25 and 1.78 +/- 0.22 vs. 0.95 +/- 0.11 mA, p = 0.001). The average episodes of ventricular tachycardia (VT) and VF per rat were significantly less in groups L and C than in group N (0.96 +/- 0.2 and 1.2 +/- 0.3 vs. 2.8 + 0.4 mA, p < 0.001). Myocardial infarct size was significantly smaller in groups L and C than in group N (34 +/- 3% and 35 +/- 3% vs. 44 +/- 3%, p = 0.031, 0.043). Endothelium-dependent vasorelaxation induced by a calcium ionophore (A23187) was increased in both groups but was only statistically significant in group C (p = 0.020).
CONCLUSIONS: Losartan and captopril have similar cardiovascular protective effects in a rat model of ischemia-reperfusion. They increased the threshold of VF, decreased mortality and decreased episodes of VT and VF, as well as decreased myocardial infarct size.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716484     DOI: 10.1016/s0735-1097(99)00592-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  Myocardial ischemia, reperfusion, and infarction in chronically instrumented, intact, conscious, and unrestrained mice.

Authors:  Heidi L Lujan; Hussein Janbaih; Han-Zhong Feng; Jian-Ping Jin; Stephen E DiCarlo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-04-25       Impact factor: 3.619

2.  AT2 receptor and apoptosis during AT1 receptor blockade in reperfused myocardial infarction in the rat.

Authors:  Bodh I Jugdutt; Vijayan Menon
Journal:  Mol Cell Biochem       Date:  2004-07       Impact factor: 3.396

3.  Inhibiting (pro)renin receptor-mediated p38 MAPK signaling decreases hypoxia/reoxygenation-induced apoptosis in H9c2 cells.

Authors:  Yan Liu; Shenglin Zhang; Dechun Su; Jinqiu Liu; Yunpeng Cheng; Lu Zou; Wenqiang Li; Yinong Jiang
Journal:  Mol Cell Biochem       Date:  2015-02-25       Impact factor: 3.396

4.  Losartan reduces mortality in a genetic model of heart failure.

Authors:  Sophie Günther; Hideo A Baba; Steffen Hauptmann; Hans-Jürgen Holzhausen; Claudia Grossmann; Karla Punkt; Tina Kusche; Larry R Jones; Ulrich Gergs; Joachim Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-10       Impact factor: 3.000

5.  The effect of polypyrrole on arteriogenesis in an acute rat infarct model.

Authors:  Shirley S Mihardja; Richard E Sievers; Randall J Lee
Journal:  Biomaterials       Date:  2008-08-03       Impact factor: 12.479

6.  Effects of early losartan therapy on ventricular late potentials in acute myocardial infarction.

Authors:  Dae-Hyeok Kim; Woong-Gil Choi; Jun Kwan; Keum-Soo Park; Woo-Hyung Lee
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-10       Impact factor: 1.468

7.  Angiotensin II and ischemic preconditioning synergize to improve mitochondrial function while showing additive effects on ventricular postischemic recovery.

Authors:  Rebeca E Nuñez; Miriam Castro; Sabzali Javadov; Nelson Escobales
Journal:  J Cardiovasc Pharmacol       Date:  2014-08       Impact factor: 3.105

8.  Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches.

Authors:  Junya Takagawa; Yan Zhang; Maelene L Wong; Richard E Sievers; Neel K Kapasi; Yan Wang; Yerem Yeghiazarians; Randall J Lee; William Grossman; Matthew L Springer
Journal:  J Appl Physiol (1985)       Date:  2007-03-08

9.  (Pro)renin receptor contributes to hypoxia/reoxygenation-induced apoptosis and autophagy in myocardial cells via the beta-catenin signaling pathway.

Authors:  X Gao; S Zhang; D Wang; Y Cheng; Y Jiang; Y Liu
Journal:  Physiol Res       Date:  2020-05-29       Impact factor: 1.881

10.  Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction.

Authors:  Doo Sun Sim; Myung Ho Jeong; Ho Chun Song; Jahae Kim; Ari Chong; Hee Seung Bom; In Seok Jeong; Sang Gi Oh; Jong Min Kim; Dae Sung Park; Jung Ha Kim; Kyung Seob Lim; Min Suk Kim; Shi Hyun Ryu; Hyun Kuk Kim; Sung Soo Kim; Su Young Jang; Jae Yeong Cho; Hae Chang Jeong; Ki Hong Lee; Keun Ho Park; Nam Sik Yoon; Hyun Ju Yoon; Kye Hun Kim; Young Joon Hong; Hyung Wook Park; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  J Korean Med Sci       Date:  2014-12-23       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.